The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Abstract
Background and Purpose— The SPARCL trial showed that atorvastatin 80 mg/d reduces the risk of stroke and other cardiovascular events in patients with recent stroke or transient ischemic attack (TIA). We tested the hypothesis that the benefit of treatment varies according to index event stroke subtype. Methods— Subjects with stroke or TIA without known coronary heart disease were randomized to atorvastatin 80 mg/d or placebo. The SPARCL primary end point was fatal or nonfatal stroke. Secondary end points included major cardiovascular events (MCVE; stroke plus major coronary events). Cox regression models testing for an interaction with treatment assignment were used to explore potential differences in efficacy based on stroke subtype. Results— For subjects randomized to atorvastatin versus placebo, a primary end point occurred in 13.1% versus 18.6% of those classified as having large vessel disease (LVD, 15.8% of 4,731 participants), in 13.1% versus 15.5% of those with small vessel disease (SVD, 29.8%), in 11.2% versus 12.7% of those with ischemic stroke of unknown cause (21.5%), in 7.6% versus 8.8% of those with TIA (30.9%), and in 22.2% versus 8.3% of those with hemorrhagic stroke (HS, 2%) at baseline. There was no difference in the efficacy of treatment for either the primary end point (LVD hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.49 to 1.02, TIA HR 0.81, CI 0.57 to 1.17, SVD HR 0.85, CI 0.64 to 1.12, unknown cause HR 0.87, CI 0.61 to 1.24, HS HR 3.24, CI 1.01 to 10.4; P for heterogeneity=0.421), or MCVEs ( P for heterogeneity=0.360) based on subtype of the index event. As compared to subjects with LVD strokes, those with SVD had similar MCVE rates (19.2% versus 18.5% over the course of the trial), and similar overall reductions in stroke and MCVEs. Conclusions— Atorvastatin 80 mg/d is similarly efficacious in preventing strokes and other cardiovascular events, irrespective of baseline ischemic stroke subtype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Short-term Prognosis After Emergency Department Diagnosis of TIA
Johnston, S. C. (2000) · JAMA · doi:10.1001/jama.284.22.2901 · Cited by 1,300
Rothwell, P. M., Giles, M. F., Chandratheva, A., Marquardt, L., Geraghty, O., Redgrave, J. N., Lovelock, C. E., Binney, L. E., Bull, L. M., Cuthbertson, F. C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61448-2 · Cited by 1,190
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Self-citationIschemic Stroke Subtypes: A Population-Based Study of Functional Outcome, Survival, and Recurrence
Petty, G. W., Brown, R. D., Whisnant, J. P., Sicks, J. D., O’Fallon, W. M., & Wiebers, D. O. (2000) · Stroke · doi:10.1161/01.str.31.5.1062 · Cited by 715
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects
Lavallée, P. C., Meseguer, E., Abboud, H., Cabrejo, L., Olivot, J.-M., Simon, O., Mazighi, M., Nifle, C., Niclot, P., Lapergue, B., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70248-x · Cited by 668
Self-citationAntithrombotic and Thrombolytic Therapy for Ischemic Stroke
Albers, G. W., Easton, J. D., Sacco, R. L., & Teal, P. (1998) · Chest · doi:10.1378/chest.114.5_supplement.683s · Cited by 617
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
Albers, G. W., Amarenco, P., Easton, J. D., Sacco, R. L., & Teal, P. (2004) · Chest · doi:10.1378/chest.126.3_suppl.483s · Cited by 466
Self-citationHelgason, C. M., & Wolf, P. A. (1997) · Stroke · doi:10.1161/01.str.28.7.1498 · Cited by 440
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Pantoni, L. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70104-6 · Cited by 3,405
Stroke risk factors, genetics, and prevention
Boehme, A. K., Esenwa, C., & Elkind, M. S. V. (2017) · Circulation Research · doi:10.1161/circresaha.116.308398 · Cited by 1,952
Amarenco, P., & Labreuche, J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70058-4 · Cited by 660
Self-citationCNS small vessel disease: A clinical review
Cannistraro, R. J., Badi, M., Eidelman, B. H., Dickson, D. W., Middlebrooks, E. H., & Meschia, J. F. (2019) · Neurology · doi:10.1212/wnl.0000000000007654 · Cited by 649
Metadata
- Authors
- Amarenco, P., Benavente, O., Goldstein, L. B., Callahan, A., Sillesen, H., Hennerici, M. G., Gilbert, S., Rudolph, A. E., Simunovic, L., Zivin, J. A., & Welch, K. M. A.
- Venue
- Stroke
- Published
- 2009-04
- Volume
- 40
- Issue
- 4
- Pages
- 1405-1409
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2006517595
- Cited by
- 271
- References
- 19
- FWCI
- 19.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes. https://app.cochat.ai/papers/10.1161/strokeaha.108.534107
- The paper
- Amarenco, P., Benavente, O., Goldstein, L. B., Callahan, A., Sillesen, H., Hennerici, M. G., Gilbert, S., Rudolph, A. E., Simunovic, L., Zivin, J. A., & Welch, K. M. A. (2009). Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes. Stroke. https://doi.org/10.1161/strokeaha.108.534107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.